Johnson & Johnson has decided to bow out of the market for respiratory syncytial virus (RSV) vaccines, abandoning a late-stage development programme that would have be
A recent Biomedical Research & Bio-Products AG phase 2 study showed that its TSST-1 vaccine is safe and effective against Staphylococcal-induced Toxic Shock Syndrome (
Merck & Co has entered into a worldwide licensing deal with Opko Health’s ModeX Therapeutics unit for a vaccine candidate against Epstein-Barr virus (EBV) that could b
An FDA advisory committee has voted that GSK’s respiratory syncytial virus vaccine (RSV) is effective and safe for use in older adults, the day after it
An FDA panel of experts has recommended approval of Pfizer’s respiratory syncytial virus (RSV) vaccine in a pair of votes, neither of which was a resounding win.
Development of a Lyme disease vaccine at Valneva, developed with partner Pfizer, has been thrown into disarray after it emerged that some clinical trial sites were not adh
Software that can be used to monitor patients with neurodegenerative disorder amyotrophic lateral sclerosis (ALS) using their voice patterns has been granted breakthrough